This inventor holds 2 USPTO granted patents. Top assignee: Otsuka Pharmaceutical Factory, Inc.. Active years: 1990-1992.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1990-1992
Title: Atsushi Shima: Innovator in Pharmaceutical Composition for Hyperlipidemia
Introduction
Atsushi Shima is a notable inventor based in Tokushima, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of hyperlipidemia. With a total of 2 patents, his work focuses on innovative methods and compositions that aim to improve health outcomes.
Latest Patents
One of Atsushi Shima's latest patents is a method for treating hyperlipidemia. This pharmaceutical composition contains carboxamide compounds represented by a specific formula. These compounds exhibit excellent activities in lowering serum lipid levels while maintaining low toxicity and high safety. Although these carboxamide compounds were developed by the inventors, their pharmacological activities for treating hyperlipidemia had not been previously identified. The novel carboxamide compounds are useful as agents for treating and preventing various diseases related to lipid levels, including hypercholesterolemia, hypertriglyceridemia, hyperphospholipidemia, and hyperlipacidemia.
Career Highlights
Atsushi Shima is currently employed at Otsuka Pharmaceutical Factory, Inc. His work at this esteemed company has allowed him to focus on developing innovative solutions for health issues, particularly those related to lipid metabolism.
Collaborations
Atsushi has collaborated with notable coworkers, including Kazuhiko Tsutsumi and Eiji Uesaka. Their combined expertise has contributed to the advancement of pharmaceutical innovations.
Conclusion
Atsushi Shima's contributions to the field of pharmaceuticals, particularly in the treatment of hyperlipidemia, highlight his role as an influential inventor. His innovative approaches and collaborations continue to pave the way for advancements in medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
